Telehealth prescribing rules: state-by-state changes in 2026
Eight states tightened controlled-substance telehealth in early 2026 after the federal DEA rule expired. Here's what changed and where you can still get care online.
By WeighedHealth Editorial
2 min readUpdated
The federal flexibilities that allowed telehealth controlled-substance prescribing without an in-person visit (in place since 2020 COVID emergency) finally expired in November 2025. The DEA's permanent rule replaced it with a narrower carve-out: 30-day controlled-substance prescriptions OK telehealth-only, anything beyond requires one in-person visit within the prior 6 months.
States that tightened further
Eight states added rules on top of the federal baseline. California, New York, Massachusetts, and Washington require synchronous (video, not async) visits for new mental-health controlled-substance prescribing. Texas, Florida, Tennessee, and Georgia preserved looser async rules in line with the federal floor.
WeighedHealth's offer pages reflect each state's eligibility per program. The state-availability matrix updates monthly. If you're in a state that tightened, expect some brands to drop you out of their async funnel during intake — that's the state law, not the brand being difficult.
What's unaffected
Non-controlled prescribing — GLP-1s, finasteride, sildenafil, tretinoin, antibiotics, SSRIs — remains async-friendly across all 50 states. The new rules apply only to controlled substances (Schedule II-V: stimulants for ADHD, benzodiazepines, opioids, ketamine).
If your treatment is on the non-controlled side, nothing changed for you. If you take Adderall, Vyvanse, Xanax, Klonopin, or Suboxone via telehealth, expect more friction — either an in-person establishing visit, or a switch to a non-controlled alternative.
Related reads
Compounded GLP-1 in 2026: the complete legal map (post-503B rule)
What 'compounded' actually means, where the law stands after the April 2026 FDA rule, what's still legitimate, what isn't, and how to read a program's compliance posture in 10 minutes.
Compounded semaglutide near me in 2026: where it's actually still available
Compounded semaglutide availability has dramatically narrowed in 2026. FDA proposed permanently ending 503B mass compounding April 30, 2026. Hims exited February 2026 amid Novo Nordisk lawsuit. State boards of pharmacy enforce at different paces. Here's the actual map of where compounded semaglutide is still findable, plus legitimate alternatives.
Orforglipron: the once-daily GLP-1 pill and what its phase 3 trial showed (2026)
Orforglipron is an investigational oral GLP-1 drug — a true once-daily pill with no food or water timing rules. Its phase 3 obesity trial showed about 11% average weight loss at 72 weeks. Here's how it compares to injections and to Rybelsus, and where it stands.